9/2/2011

Merck & Co.'s atypical antipsychotic Saphris, or asenapine maleate, is associated with serious allergic reactions, including angioedema and anaphylaxis, according to an FDA alert. The agency's Adverse Event Reporting System lists 52 hypersensitivity cases among Saphris users, with some reactions occurring simultaneously or after the first dose.

Related Summaries